ArticlePituitary2026
Beyond biochemical control: factors associated with quality of life in patients with acromegaly.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeQuality of life (QoL) impairment may persist in acromegaly despite biochemical control. We evaluated disease-specific and generic QoL, psychological symptom burden, and associated factors.
methodsIn this cross-sectional study, 90 patients completed the Acromegaly Quality of Life Questionnaire (AcroQoL), EQ-5D-3 L, EQ-VAS, Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Demographic, clinical, biochemical, and treatment-related data were retrieved from records. Correlation analyses and hierarchical multivariable linear regression were used to assess factors associated with total AcroQoL.
resultsThe cohort included 46 female and 44 male patients; 86 were in biochemical remission. Median total AcroQoL, BDI, BAI, EQ-5D index, and EQ-VAS scores were 76.7, 10.5, 9.0, 0.7, and 80.0, respectively. Female patients had lower total AcroQoL scores and higher anxiety and depression scores than male patients. Higher educational status was associated with better AcroQoL and lower BDI scores. In Model 1, female sex was associated with lower total AcroQoL; however, this association became non-significant after moderate-to-severe depressive symptoms were added in Model 2. Depressive symptom status showed the largest independent association with lower total AcroQoL among model variables (B = - 17.56, 95% CI - 25.23 to - 9.89, p < 0.001), while higher educational status remained independently associated with better QoL. R
conclusionIn this predominantly biochemically controlled cohort, disease-specific QoL was more closely associated with depressive symptom burden and educational status than with the clinical variables examined. These findings support routine assessment of psychological symptoms and patient-reported outcomes during long-term care.
Indexed as
Identifiers
42622888What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.